Company shares are trading at $1.59 just a bit higher than $1.47, the stock’s 50 day moving average and which is quite a bit higher than the 200 day moving average of $1.32. The 50 day moving average was up $0.11 whereas the 200 day moving average was up $0.27 or +20.1202%. Aptose Biosciences, Inc. shares had a trading volume of 567K in the last trading session. Shares saw a steep increase in trading volume of 92.00% over the normal average daily volume.
Traders are a little more bullish on the company recently as implied by the motion in short interest. The firm experienced a fall in short interest of -7.55% as of October 13, 2017 from the last reporting period. Short shares fell from 750,731 to 694,031 over that timeframe. The short-interest ratio decreased to 3.0 and the short interest percentage is 0.03% as of October 13.
A few notable investment firms have updated their holdings. As of quarter end Bank Of America Corp /de/ had sold a total of 4,500 shares trimming its position 93.8%. The value of the investment in Aptose Biosciences, Inc. went from $7,000 to $0 decreasing 100.0% for the reporting period. Jane Street Group, LLC augmented its ownership by buying 2,657 shares an increase of 24.8% as of 03/31/2017. Jane Street Group, LLC owns 13,376 shares worth $14,000. The value of the position overall is down by 6.7%.
As of the end of the quarter Renaissance Technologies LLC had acquired 6,300 shares growing its holdings by 25.3%. The value of the investment in APTO increased from $25,000 to $39,000 a change of 56.0% quarter to quarter. Tower Research Capital LLC (trc) grew its holdings by buying 2,400 shares an increase of 1,200.0% from 03/31/2017 to 06/30/2017. Tower Research Capital LLC (trc) controls 2,600 shares with a value of $4,000. The total value of its holdings increased inf%.
In the latest earnings report the EPS was $-0.74 and is projected to be $-0.88 for the current year with 24,027,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-0.16 and the next full year EPS is anticipated to be $-0.71.
Aptose Biosciences Inc. (Aptose), launched on November 1, 2006, is a clinical-stage biotechnology company. The Company is involved in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. The Business’s product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products..